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ABSTRACT
Background: Very few data exist on coronary obstruction 
following transcatheter aortic valve implantation (TAVI) for 
degenerative bioprosthetic valves (valve-in-valve [ViV]). The 
present trial evaluated, through a systematic review of the 
literature, the clinical characteristics, management and clinical 
outcomes of patients with coronary obstruction after ViV-TAVI. 
Methods: Studies published between 2002 and 2013 evalua-
ting coronary obstruction as a complication of ViV-TAVI were 
identified using a systematic electronic search. Data on the 
clinical and procedural characteristics, management of the 
complication, and clinical outcomes were analyzed. Results: 
A total of four publications describing seven patients were 
identified. Most patients (71%) were women, with mean age 
of 82 ± 5 years, and STS-PROM score of 9.4 ± 2.6%. Mean 
left coronary artery (LCA) ostium height and aortic root width 
were 8.8 ± 1.5 mm and 28.0 ± 5.0 mm, respectively. Most 
patients had stented bioprosthetic valves with externally 
mounted leaflets or stentless aortic bioprosthesis, and the LCA 
was involved in all patients. Percutaneous coronary interven-
tion (PCI) was attempted in all patients and was successful in 
four (57%). In-hospital mortality was 42.9% (three cases), all 
of them after failed PCI. Conclusions: Coronary obstruction 
following ViV-TAVI occurred more frequently in women with 
stented bioprosthetic valves with externally mounted leaflets 
or with stentless bioprosthesis. The LCA was involved in all 
cases and PCI was successful in 60% of them. Continued 
1 Post-Graduate (Doctorate) by Quebec Heart & Lung Institute, Laval 
University. Quebec, Canada.
2 Fellow, Quebec Heart & Lung Institute, Laval University. Quebec, 
Canada.
3 Fellow, Quebec Heart & Lung Institute, Laval University. Quebec, 
Canada.
4 Post-Graduate (Doctorate) by Quebec Heart & Lung Institute, Laval 
University. Quebec, Canada.
5 Fellow, Quebec Heart & Lung Institute, Laval University. Quebec, 
Canada.
6 Radiologist-chief, Quebec Heart & Lung Institute, Laval University. 
Quebec, Canada.
7 Heart Surgeon, Quebec Heart & Lung Institute, Laval University. 
Quebec, Canada.
8 Chief, Cardiology, Quebec Heart & Lung Institute, Laval University. 
Quebec, Canada.
9 Coordinator, Research Center on Structural Heart Diseases, Quebec 
Heart & Lung Institute, Laval University. Quebec, Canada.
10 Heart Surgeon, Chief, TAVI Program, Quebec Heart & Lung Institute, 
Laval University. Quebec, Canada.
11 Chief, Department of Hemodynamics, Quebec Heart & Lung Institute, 
Laval University. Quebec, Canada.
Correspondence to: Henrique Barbosa Ribeiro. Avenida São Gabriel, 
201, sala 1.304 – São Paulo, SP, Brazil – CEP 01435-001
E-mail: henriquebribeiro@me.com
Received: 09/14/2013 • Accepted: 11/24/2013
Original Article
RESUMO
Obstrução Coronária Após Implante de Válvula 
Aórtica por Cateter para o Tratamento de Bioprótese 
Valvular Cirúrgica com Disfunção:  
Revisão Sistemática da Literatura
Introdução: Há poucos dados na literatura que avaliam a ob-
strução coronária após implante transcateter de válvula aórtica 
(transcatheter aortic valve implantation [TAVI]) para o tratamento de 
disfunção de bioprótese aórtica (valve-in-valve – ViV). O presente 
estudo avaliou, por meio de revisão sistemática da literatura, as 
características clínicas, o manejo e os desfechos clínicos de pa-
cientes com obstrução coronária após TAVI-ViV. Métodos: Estudos 
publicados entre 2002 e 2013 avaliando a obstrução coronária 
como complicação de TAVI-ViV foram identificados por meio 
de busca eletrônica sistemática. Foram avaliados dados basais 
sobre as características clínicas e do procedimento, manejo da 
complicação e desfechos clínicos. Resultados: Foram identifica-
das, no total, quatro publicações descrevendo sete pacientes. A 
maioria dos pacientes era do sexo feminino (71%), sendo a média 
de idade de 82 ± 5 anos, com STS-PROM de 9,4 ± 2,6%. As 
médias da altura do tronco da artéria coronária esquerda (TCE) e 
o diâmetro médio da raiz aórtica foram de 8,8 ± 1,5 mm e 28,0 
± 5,0 mm, respectivamente. A maioria dos pacientes apresentava 
biopróteses com suporte e folhetos montados externamente, ou 
eram próteses sem suporte (stentless) e o TCE foi envolvido em 
todos os casos. A intervenção coronária percutânea (ICP) foi 
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efforts may help identify the factors associated with this 
complication so that appropriate prevention measures may 
be implemented.
 
 
 
 
 
 
 
DESCRIPTORS: Aortic valve. Heart valve prosthesis implanta-
tion. Coronary occlusion.
“trans catheter valve implantation”, “transcatheter aortic 
valve replacement”, “transcatheter heart valve”, “heart 
valve prosthesis implantation”, “coronary stenosis”, 
“coronary occlusion, coronary obstruction”, “prior sur-
gical bioprosthesis” and “valve-in-valve”. Other studies 
were evaluated through manual research of secondary 
sources, including references of primary articles (back-
ward snowballing) and contact with international experts.
The quotations were selected based on title/abstract 
by two independent reviewers (HBR and LNF), and 
retrieved as complete manuscripts when considered 
potentially relevant. Disagreements were resolved by 
consensus, aiming to gather all reports and relevant 
case series on coronary obstruction after TAVI-ViV. The 
published articles which included only the incidence 
of the complication were excluded from this analysis.
Data gathered included the basal clinical character-
istics, beyond echocardiographic and tomography (CT) 
features. The CT variables included data from LMCA 
height in relation to the aortic annulus and aortic root 
and annulus diameters. Procedural data, such as type 
and size of transcatheter valve used, type of approach, 
clinical picture, and management of coronary obstruc-
tion were also evaluated. Finally, data on in-hospital 
mortality were also recovered. 
Categorical variables were reported as n (%) and 
continuous variables as mean ± standard deviation. All 
analyzes were performed using SAS statistical package, 
version 9.3 (SAS Institute Inc., Cary, NC, United).
RESULTS
A total of four publications were identified, des 
cribing a total of seven patients who had coronary 
obstruction related to TAVI-ViV.5-8 All studies were case 
reports, except for one multicenter trial that included 
three cases of coronary obstruction. The main baseline 
clinical characteristics were available for all patients. 
CT data on the height of the LMCA ostium, aortic 
annulus, and aortic root measures were reported in 
four, four, and three patients, respectively. Clinical and 
tenta da em todos os pacientes, tendo sucesso em quatro deles 
(57%). A mortalidade intra-hospitalar foi 42,9% (três casos), 
todos após ICP sem sucesso. Conclusões: A obstrução coronária 
após TAVI-ViV ocorreu mais frequentemente em mulheres com 
bioprótese com suporte e folheto montado externamente ou 
com bioprótese sem suporte. O TCE foi envolvido em todos os 
casos e a ICP foi realizada com sucesso em 60% deles. Esforços 
contínuos poderão auxiliar na detecção dos fatores associados 
a essa complicação, no intuito de se implementarem medidas 
apropriadas para sua prevenção.
 
DESCRITORES: Valva aórtica. Implante de prótese de valva 
cardíaca. Oclusão coronária.
T he transcatheter aortic valve implantation (TAVI) has been established as the standard for the treatment of patients with severe symptomatic aortic stenosis 
considered inoperable, and as an alternative to those 
considered at high risk for aortic valve replacement 
surgery.1,2 However, TAVI has also been associated with 
very rare complications, but many of them fatal, such 
as coronary obstruction, which is typically related to 
the displacement of the calcified native leaflets of the 
valve toward coronary ostia.
Recently, a systematic review of the literature on 
symptomatic coronary obstruction as a complication 
of TAVI was conducted, which included a total of 24 
cases, all of them described in isolation as case reports 
or as small series of cases.3 Such review demonstrated 
that coronary obstruction after TAVI occurred more 
often in women and in patients receiving expansible 
valve by balloon, and the left main coronary artery 
(LMCA) was the most often involved vessel. How-
ever, that study excluded procedures in patients with 
previous surgical bioprosthesis (valve-in-valve [ViV]). 
Moreover, a recent multicenter registry, which included 
over 6,500 patients, suggested that this complication 
could be up to four times more frequent in patients 
with surgical prostheses, similarly to those reported in 
the ViV global registry.4
However, no study to date has evaluated specifi-
cally this complication in a ViV population. Thus, the 
present study aimed to evaluate baseline characteristics, 
management, and clinical outcomes of coronary obstruc-
tion as a complication of TAVI in patients with previous 
surgical aortic bioprosthesis through a systematic review.
METHODS
All relevant articles in English on TAVI and coronary 
obstruction in patients with previous surgical bioprosthesis 
published between December 2002 and September 2013 
were systematically searched at BioMedCentral (http://
www.biomedcentral.com), Google Scholar (http://www.
scholar.google.com), and PubMed (http://www.pubmed.
gov). The following key terms were used: “aortic stenosis”, 
Ribeiro et al. 
Coronary Obstruction After TAVI
Rev Bras Cardiol Invasiva. 
2013;21(4):311-8
313
procedural data about clinical presentation, diagnosis, 
and management of the coronary occlusion were 
available for all patients. All studies reported data on 
in-hospital outcomes.
The main clinical, echocardiographic, CT, and 
procedural characteristics to which the patients were 
submitted are listed in Tables 1 (individual data) and 
2 (means). The mean age of the study population was 
82 ± 5 years, and most were female (71.4%). Data 
from CT revealed a mean height of LMCA of 8.8 ± 
1.5 mm and a mean aortic root diameter of 28.0 ± 5.0 
mm. The Edwards Balloon Expandable Valve® (Edwards 
Lifesciences, Irvine, CA) was used in five patients, and 
a self-expanding valve, CoreValve® (Medtronic, Min-
neapolis, MN), was used in two patients.
The main data on the clinical presentation and 
management adopted in relation to coronary obstruc-
tion are listed in Table 3 (individual data) and Table 4 
(means). The LMCA was involved in all patients (in one 
of them, together with right coronary artery); all patients 
presented significant and sustained hypotension, and 
most of them (57.1%) had electrocardiographic changes 
of ST-segment. The diagnosis of coronary obstruction 
was established by coronary angiography for all patients, 
and in all of them the obstruction was related to the 
displacement of bioprosthesis leaflets.
Percutaneous coronary intervention (PCI) was 
attem pted in all patients, and was successful in four 
of them (57.1%). The three cases of failure of PCI 
occurred by: inability to cross the obstruction with 
the coronary guide wire, requiring emergency CABG; 
failure to restore the coronary blood flow, despite the 
TABLE 1 
Baseline clinical and procedural characteristics 
Study
Age 
(years) Gender
Bioprosthesis 
type
Surgical 
bioprosthesis 
name
Bioprosthesis 
size (mm)
Previous 
CABG
STS 
score 
(%)
Mean 
aortic 
gradient 
(mmHg)
Aortic 
annulus 
(mm)
Aortic 
root 
(mm)
LMCA 
height 
(mm)
Access TAVI  
type
TAVI 
size 
(mm)
Fiorina  
et al.5
82 M Supportless 
(stentless)
CryoLife-
O’Brien®
25 No – – – 33 10 TF CoreValve® 29
Gurvitch  
et al.6
86 F Supported Mitroflow® 21 Yes 12,9 87 18 – – TA Sapien® 23
Gurvitch  
et al.6
78 F Supported Mitroflow® 21 Yes – 44 – – – TF CoreValve® 26
Chakravarty 
et al.7
79 F Supportless 
(stentless)
St. Jude 23 No 6,1 - – – 7,4 TF Sapien® 23
Ribeiro  
et al.8
80 F Supportless 
(stentless)
Toronto 24 No 8,1 22 20 23,2 9,7 TF Sapien® 23
Ribeiro  
et al.8
91 F Supported SPV® 21 Yes 10,3 43 18 – – TF Sapien® 23
Ribeiro  
et al.8
80 M Supportless 
(stentless)
St. Jude 23 No 9,7 15 21 28 8,2 TF Sapien XT® 23
CABG = coronary artery bypass graft surgery; STS = Society of Thoracic Surgeons; LMCA = left main coronary artery; M = male; TF = transfemoral; F = female; 
TA = transapical.
TABLE 2 
Basal clinical, echocardiographic, CT, and procedural 
characteristics of the population studied
Clinical variables (n = 7)
Age, years 82.3 ± 4.6
Female, n (%) 5 (71.4)
NYHA III-IV class, n (%) 6 (85.7)
Previous CABG surgery, n (%) 4 (57.1)
STS-PROM score, % 9.4 ± 2.6
Echocardiographic and computed
tomography data
Mean aortic gradient, mmHg 42.2 ± 28.1
Aortic valve area, cm2 0.43 ± 0.09
Aortic annulus, mm 19.1 ± 1.8
Height of the left main coronary artery, 
mm 
8.8 ± 1.5
Aortic root diameter, mm 28.0 ± 5.0
Data from the procedure 
Approach, n (%) 
 Transfemoral 6 (85.7)
 Transapical 1 (14.3)
Valve type, n (%) 
 Sapien® and Sapien XT® 5 (71.4)
 CoreValve® 2 (28.6)
CT = computed tomography; CABG = coronary artery bypass 
graft surgery; NYHA = New York Heart Association.
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successful implantation of the stent, which led to a 
persistent cardiogenic shock and death; and inability to 
advance the stent. Hemodynamic support was needed 
in four patients (57.1%) and the in-hospital mortality 
was 42.9%. All patients undergoing a successful PCI 
survived and were discharged from the hospital; no 
case showed stent thrombosis or neorevascularization.
DISCUSSION
The present systematic review assessing symptomatic 
coronary obstruction following TAVI for treatment of 
surgical bioprosthetic valve dysfunction observed that 
the complication occurred more often in women and in 
patients previously treated with supportless prostheses, or 
in those supported and with leaflets externally mounted. 
In such cases, the mean height of the LMCA ostium was 
~ 8 mm and the mean diameter of the aortic root was 
~ 28 mm. The clinical picture included more often a 
significant and sustained hypotension, besides changes 
in ST segment; a PCI was attempted in all cases, and 
was successful in approximately 60% of them.
However, mechanical hemodynamic support and 
conversion for CABG were still required in 57% and 
14% of patients, respectively. There were no cases of 
acute stent thrombosis or of neorevascularization, and 
the rate of in-hospital mortality was 42.9% (there were 
no deaths in patients undergoing successful PCI).
Coronary obstruction following TAVI has been a 
concern since the first experimental studies,9,10 having 
been described in 2006 in the first experiment in hu-
mans for the treatment of native aortic valve stenosis.11 
The first case of coronary obstruction as a complication 
of TAVI-ViV procedure was reported in 2011.6 Since 
then, the reported incidence for coronary obstruction 
in different studies has been generally < 1%.
However, in a large multicenter registry recently 
published on coronary obstruction, with over 6,500 
patients, the incidence in native aortic valves was 
0.66%, much lower than the 2.48% of the patients 
submitted to previous surgical prostheses.8 This inci-
dence is similar to that reported of 3.5%, described 
in a recent registry conducted worldwide considering 
only TAVI-ViV (Valve-in-Valve Global Registry), includ-
ing 202 patients,4 and corroborates the presence of 
TABLE 3 
Clinical picture and conduct
Study
Clinical picture Treatment
Successful 
ATC
Stent  
type
Hemodynamic 
support 
needed
Length 
of stay 
(days)
In-hospital 
mortality
Coronary 
obstruction
Significant 
hypotension
ST-segment 
changes
Ventricular 
arrhythmias 
or CPR CPI CABG
Fiorina et al.5 LMCA Yes No No Yes No Yes CS Yes - No
Gurvitch et al.6 Both Yes Yes No Yes Yes No - Yes 1 Yes
Gurvitch et al.6 LMCA Yes Yes Yes Yes No No - Yes 0 Yes
Chakravarty et al.7 LMCA Yes Yes No Yes No Yes DES No - No
Ribeiro et al.8 LMCA Yes No No Yes No Yes DES No 3 No
Ribeiro et al.8 LMCA Yes No Yes Yes No No - Yes 3 Yes
Ribeiro et al.8 LMCA Yes Yes No Yes No Yes DES No 4
CPR = cardiopulmonary resuscitation; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; LMCA = left 
main coronary artery; CS = conventional stent; DEA = drug-eluting stent.
TABLE 4 
Clinical picture and conduct (n = 7)
Picture/conduct 
Coronary occlusion, n (%) 
Left main coronary artery 6 (85.7)
Both coronary arteries 1 (14.3)
Clinical picture, n (%) 
Severe persistent hypotension 7 (100)
ST-segment changes 4 (57.1)
ST-segment elevation 1 (14.3)
Treatment, n (%) 
Attempted percutaneous coronary 
intervention 
7 (100)
Successful 4 (57.1)
Unsuccessful 3 (42.9)
Inability to cross the lesion with the 
guide wire 
1 (14.3)
Inability to advance the stent 1 (14.3)
Stent implanted but without flow 1 (14.3)
Complications, n (%) 
Need for hemodynamic support 4 (57.1)
Conversion to CABG 1 (14.3)
In-hospital death 3 (42.9)
CABG = coronary artery bypass graft.
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previous surgical bioprosthesis as a potential risk factor 
for this complication. The rates of coronary obstruction 
in recent studies evaluating this complication, both in 
native aortic valves and in surgical bioprostheses, are 
summarized in Table 5.
Factors associated with coronary obstruction 
after TAVI
The mechanism associated with coronary obstruc-
tion after TAVI-ViV has been the displacement of the 
bioprosthesis leaflet towards the coronary ostium in 
all patients; no cases of coronary obstruction related 
to the metal frame of transcatheter valves, nor to their 
leaflets, have been reported.3,8 Furthermore, according 
to the TAVI-ViV Global Registry,4 the coronary obstruc-
tion following TAVI-ViV was more frequent in supported 
bioprosthesis leaflets and in externally mounted leaflets 
(especially the Mitroflow® prosthesis) and also with 
supportless bioprostheses. In the case of the Mitroflow® 
prosthesis, the relatively long (~ 13 mm) leaflets exter-
nally mounted on the supports (with stent), rather than 
internally as in most other supported prostheses, may be 
associated with a higher rate of coronary obstruction.6 
In addition, the supportless bioprostheses (stentless) may 
also be associated with an increased risk of this com-
plication. These bioprostheses are generally implanted 
in a supra-annular position, resulting in a shortening 
of the position of the coronary ostia in relation to the 
valve leaflets, which, together with the rodless stents, 
may facilitate an interaction of the prosthesis with the 
aortic wall and the coronary ostium (Figure 1).
Additionally, and in agreement with previous stu-
dies on TAVI in native aortic valves,3,8 the presence of 
coronary ostia located in a lower position, and of a 
narrow Valsalva sinus, were also identified as potential 
risk factors for this complication in cases of ViV. In this 
sense, among patients with available data of CT in this 
trial, the mean height of LMCA was 8.8 mm, similar to 
that found in a recent multicenter registry (10.6 mm) and 
much lower than that of 13.4 mm observed in control 
patients without coronary occlusion (P < 0.001).8 This 
height is also significantly lower (~ 5 mm) than that 
reported in previous CT studies in patients with and 
without aortic stenosis (systematically >  13 mm).12-14
Although the height of the coronary ostium is an 
important risk factor associated with coronary obstruc-
tion after TAVI, it was demonstrated that some patients 
had this complication despite of an LMCA height > 
12 mm, indicating that other factors (such as a nar-
row aortic root) that left little room to accommodate 
the aortic leaflets also were potential risk factors for 
coronary obstruction after TAVI.3,8 In fact, in the pres-
ent study, the mean diameter of the aortic root was 
28.0 mm, comparable to that observed in patients 
with coronary obstruction in native aortic valves 
(28.0 mm vs. 31.9 mm in controls.; P <  0.001).8 The 
TABLE 5 
Data from large registries of transcatheter aortic valve implantation assessing coronary  
obstruction in the native aortic valve and in patients with previous surgical bioprosthesis
Study n Valve/approach Transfemoral Transapical All procedures
Multicentric registry 
on coronary 
obstruction8
6,688 Total 30/4,846 (0.62%) 13/1,531 (0.85%) 44/6,688 (0.66%)
Sapien® – – 37/4,533 (0.82%)
CoreValve® – – 7/2,066 (0.34%)
Valve-in-valve – – 3/121 (2.48%)
Valve-in-Valve 
Global Registry4
202 Total – – 7/202 (3.5%)
Sapien® – – 3/78 (3.8%)
CoreValve® – – 4/124 (3.2%)
Supported prosthesis – – 4/155 (2.6%)
Supportless prosthesis – – 3/47 (6.4%)
Figure 1 – Surgical bioprostheses that have been associated with coronary 
obstruction after transcatheter aortic valve implantation.
Supported externally 
mounted and brochures
Trifects 
(St. Jude Medical)
Toronto SPV® 
(St. Jude Medical)
Unsupported
Freestyle (Medtronic) Freedom (Sorin)
Mitroflow® (Sorin) Cryolife O’Brien®
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clinical characteristics of patients who had coronary 
obstruction following TAVI-ViV revealed a mean age 
(82 years) and risk profile (mean STS-PROM score = 
9.4%) similar to those reported in most previous studies 
on TAVI. Conversely, up to 71% of patients who had 
this complication were women, a little higher value 
compared to the prevalence of ~ 50% of women in 
most studies on TAVI.3 It has been previously dem-
onstrated that women generally have lower coronary 
ostium heights and a smaller diameter of aortic roots 
when compared to men, which could partly explain 
the higher incidence of complications in females.14,15 
Moreover, it has been shown that the position of LMCA 
ostium is lower, when compared to the right coronary 
artery, which could also explain why this complication 
involves most often the LMCA.12-14,16,17
Regarding the characteristics of the procedure, most 
of the reported cases of patients who had coronary ob-
struction following TAVI in native aortic valves received 
a balloon expandable prosthesis (Table 5). In the present 
study, despite having found more cases with the balloon 
expandable valves, the authors had no domain over the 
entire population at risk to take definitive conclusions 
if this complication is also more frequent with balloon 
expandable valves in the TAVI-ViV context. Furthermore, 
in a recent TAVI-ViV Global Registry, the risk of coronary 
obstruction was similar with both types of valves (3.2% 
of cases with self-expandable prosthesis versus 3.8% 
for balloon-expandable prosthesis). Future studies will 
have to assess whether there is an interaction between 
the type of valve and the risk of coronary obstruction 
in the context of TAVI-ViV.
Clinical picture and conduct in coronary 
obstruction after TAVI
All patients had significant hypotension that persisted 
after the valve implantation, and approximately 50% 
of them exhibited ST segment changes. This clinical 
finding can be explained by the fact that LMCA was 
the most commonly involved vessel.3,8 Likewise, in the 
presence of significant and sustained hypotension after 
implantation of the valve, especially in the presence 
of an electrocardiographic change, aortographic and/
or echocardiographic studies should be immediately 
performed to verify the presence of coronary obstruc-
tion or of a new abnormality of segmental contraction, 
respectively.
In the present study, PCI was attempted in all 
patients, but this procedure was not successful in ap-
proximately half of them. Importantly, the failure of PCI 
was associated with in-hospital mortality in all cases, 
which led to a high mortality rate (around 50%). This 
high mortality rate is similar to that reported in a recent 
multicenter registry on coronary obstruction (41%) and 
also reported in TAVI – ViV global registry (57.1%).4,8 
These very high mortality rates reinforce the fact that 
this procedure should be performed in highly experi-
enced centers with the necessary surgical resources, 
in order to quickly restore the coronary flow, either 
by PCI or even coronary artery bypass graft surgery, 
in case of PCI failure. Additionally, as the cannulation 
of the coronary artery could be not an easy task due 
to the presence of the transcatheter prosthesis metal 
structure, or even of the valve complex, especially 
in patients with a low coronary ostium and a narrow 
sinus of Valsalva, the coronary protection with a wire 
guide (Figure 2) or even the preventive positioning of 
a coronary stent could avoid the deleterious effect of 
this complication.7
Limitations of the trial
This trial has the limitations inherent to a systematic 
review, which collects only the information described 
in publications, in such a way that relevant information 
that may be omitted in these publications could add 
important data about this complication for this specific 
subgroup. Furthermore, imaging data (especially CT) 
were not available in all cases reported. Finally, all 
articles retrieved were case reports or small series of 
cases, preventing a comparison with all the population 
under risk submitted to TAVI.
CONCLUSIONS
Coronary obstruction remains a rare complication 
of TAVI, but this is a potentially fatal event and appears 
be more frequent in the context of ViV procedures. The 
baseline characteristics of the reported cases suggest that 
this complication occurs more often in women previously 
submitted to the implantation of a supportless aortic 
prosthesis (stentless), or of supported prostheses with 
externally mounted leaflets. The inherent characteristics 
of such prostheses, for instance, long leaflets, a shallow 
suture annulus, a supra-annular position, and lack of 
support for the rods, along with anatomical features like 
low-position ostia and a shallow sinus of Valsalva, may 
facilitate the interaction of the prosthesis with the aortic 
wall and the coronary ostium. Regarding the clinical 
picture, the occurrence of a significant and sustained 
hypotension and of ST segment changes immediately 
after valve implantation requires the exclusion of this 
complication. Percutaneous coronary intervention was 
possible in ~ 60% of patients, with a high mortality 
rate, reinforcing the fact that these procedures should 
be performed only in highly specialized centers and 
that additional strategic measures, such as the protection 
of a guide wire, could be adopted in the presence of 
risky clinical or anatomic parameters. Further prospec-
tive studies, including consecutive series of patients 
undergoing ViV transcatheter implantation of aortic valve 
with this complication, are needed to better assess the 
predictors and the most appropriate clinical conduct 
for this important complication.
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